110 related articles for article (PubMed ID: 10656273)
1. Effect of edetate calcium disodium on yttrium-90 activity in bone of mice.
Watanabe N; Oriuchi N; Tanada S; Murata H; Inoue T; Kim EE; Sasaki Y; Endo K
Ann Nucl Med; 1999 Dec; 13(6):397-400. PubMed ID: 10656273
[TBL] [Abstract][Full Text] [Related]
2. Localization of indium-111 in human malignant tumor xenografts and control by chelators.
Watanabe N; Oriuchi N; Endo K; Inoue T; Tanada S; Murata H; Kim EE; Sasaki Y
Nucl Med Biol; 1999 Oct; 26(7):853-8. PubMed ID: 10628568
[TBL] [Abstract][Full Text] [Related]
3. CaNa2EDTA for improvement of radioimmunodetection and radioimmunotherapy with 111In and 90Y-DTPA-anti-CEA MAbs in nude mice bearing human colorectal cancer.
Watanabe N; Oriuchi N; Endo K; Inoue T; Kuroki M; Matsuoka Y; Tanada S; Murata H; Kim EE; Sasaki Y
J Nucl Med; 2000 Feb; 41(2):337-44. PubMed ID: 10688120
[TBL] [Abstract][Full Text] [Related]
4. Yttrium-90-labeled human macroaggregated albumin for internal radiotherapy: combined use with DTPA.
Watanabe N; Oriuchi N; Endo K; Inoue T; Tanada S; Murata H; Sasaki Y
Nucl Med Biol; 1999 Oct; 26(7):847-51. PubMed ID: 10628567
[TBL] [Abstract][Full Text] [Related]
5. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
[TBL] [Abstract][Full Text] [Related]
6. In-vivo tissue uptake and retention of Sn-117m(4+)DTPA in a human subject with metastatic bone pain and in normal mice.
Swailem FM; Krishnamurthy GT; Srivastava SC; Aguirre ML; Ellerson DL; Walsh TK; Simpson L; Shah J
Nucl Med Biol; 1998 Apr; 25(3):279-87. PubMed ID: 9620634
[TBL] [Abstract][Full Text] [Related]
7. [Biokinetics of tumor-affinity yttrium preparations--2].
Schomäcker K; Hientzsch B; Franke WG; Scheidhauer K; Scharl A; Jantsch K; Shukla SK; Limouris G; Fischer T; Schicha H
Nuklearmedizin; 1995 Oct; 34(5):207-14. PubMed ID: 7479096
[TBL] [Abstract][Full Text] [Related]
8. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the in vivo biodistribution of yttrium-labeled isomers of CHX-DTPA-conjugated monoclonal antibodies.
Kobayashi H; Wu C; Yoo TM; Sun BF; Drumm D; Pastan I; Paik CH; Gansow OA; Carrasquillo JA; Brechbiel MW
J Nucl Med; 1998 May; 39(5):829-36. PubMed ID: 9591585
[TBL] [Abstract][Full Text] [Related]
10. Two ⁹⁰Y-labeled multimeric RGD peptides RGD4 and 3PRGD2 for integrin targeted radionuclide therapy.
Liu Z; Shi J; Jia B; Yu Z; Liu Y; Zhao H; Li F; Tian J; Chen X; Liu S; Wang F
Mol Pharm; 2011 Apr; 8(2):591-9. PubMed ID: 21247151
[TBL] [Abstract][Full Text] [Related]
11. 90Y-labeled antibody uptake by human tumor xenografts and the effect of systemic administration of EDTA.
Rowlinson-Busza G; Snook D; Epenetos AA
Int J Radiat Oncol Biol Phys; 1994 Mar; 28(5):1257-65. PubMed ID: 8175414
[TBL] [Abstract][Full Text] [Related]
12. Improved kinetic stability of DTPA- dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives.
Béhé M; Becker W; Gotthardt M; Angerstein C; Behr TM
Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1140-6. PubMed ID: 12768330
[TBL] [Abstract][Full Text] [Related]
13. Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma.
Postema EJ; Frielink C; Oyen WJ; Raemaekers JM; Goldenberg DM; Corstens FH; Boerman OC
Cancer Biother Radiopharm; 2003 Aug; 18(4):525-33. PubMed ID: 14503946
[TBL] [Abstract][Full Text] [Related]
14. D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake.
Bernard BF; Krenning EP; Breeman WA; Rolleman EJ; Bakker WH; Visser TJ; Mäcke H; de Jong M
J Nucl Med; 1997 Dec; 38(12):1929-33. PubMed ID: 9430472
[TBL] [Abstract][Full Text] [Related]
15. [Synthesis of tumor affinity label Yb-169- and Y-90- porphyrin complexes and animal experimental investigations with various Yb-169-porphyrins].
Schomäcker K; Gaidouk MI; Rumyantseva VD; Fischer T; Löhr H; Salditt S; Liebenhoff S; Schicha H
Nuklearmedizin; 1999; 38(7):285-91. PubMed ID: 10599068
[TBL] [Abstract][Full Text] [Related]
16. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model.
Janssen ML; Oyen WJ; Dijkgraaf I; Massuger LF; Frielink C; Edwards DS; Rajopadhye M; Boonstra H; Corstens FH; Boerman OC
Cancer Res; 2002 Nov; 62(21):6146-51. PubMed ID: 12414640
[TBL] [Abstract][Full Text] [Related]
17. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.
Verel I; Visser GW; Boellaard R; Boerman OC; van Eerd J; Snow GB; Lammertsma AA; van Dongen GA
J Nucl Med; 2003 Oct; 44(10):1663-70. PubMed ID: 14530484
[TBL] [Abstract][Full Text] [Related]
18. Reduction of skeletal accumulation of radioactivity by co-injection of DTPA in [90Y-DOTA0,Tyr3]octreotide solutions containing free 90Y3+.
Breeman WA; De Jong MT; De Blois E; Bernard BF; De Jong M; Krenning EP
Nucl Med Biol; 2004 Aug; 31(6):821-4. PubMed ID: 15246375
[TBL] [Abstract][Full Text] [Related]
19. Yttrium-90-EDTMP: a radiotherapeutic agent in the treatment of leukaemias.
Keeling AA; Vaughan AT; Beaney RP
Br J Cancer; 1989 Jul; 60(1):74-8. PubMed ID: 2803919
[TBL] [Abstract][Full Text] [Related]
20. Biodistribution and dosimetry of pretargeted monoclonal antibody 2D12.5 and Y-Janus-DOTA in BALB/c mice with KHJJ mouse adenocarcinoma.
Lubic SP; Goodwin DA; Meares CF; Song C; Osen M; Hays M
J Nucl Med; 2001 Apr; 42(4):670-8. PubMed ID: 11337558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
